Co-founded by Dr. Aran, Nanosens developed the technology that combined the robust specificity of CRISPR with the dynamic sensitivity of graphene into the CRISPR-Chip technology, which has the potential to detect genetic mutations within minutes. Nanosens will now be part of Cardea’s Innovation Partnership Program, which enables Nanosens to build breakthrough science on top of Cardea’s IP-protected graphene biosensors.
Merger Announced Between NanoSens and Cardea
September 14, 2019